Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Document › Details

Roche. (12/12/14). "Press Release: Changes in Roche Board of Directors and Enlarged Corporate Executive Committee". Basel.

Organisations Organisation Roche Holding AG
  Group Roche (Group)
  Organisation 2 Genentech (Group)
  Group Roche (Group)
Products Product pharmaceutical
  Product 2 diagnostics (medical/biological)
Persons Person Poussot, Bernard (Wyeth Pharmaceuticals 200801 promoted CEO before COO since 200701 joined Wyeth 1986)
  Person 2 Varney, Michael D. (Roche 201501 promoted Head of gRED before Genentech 200610 VP Small Molecule Drug Discovery)
     


At its December meeting, the Board of Directors (BoD) of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015.

All current members of the BoD will stand for re-election:

Name Board member since

Dr. Christoph Franz (as Chairman) 2011
André Hoffmann 1996
Professor Dr. Pius Baschera 2007
Professor Sir John Irving Bell 2001
Paul Bulcke 2011
Dame DeAnne Julius 2002
Dr. Andreas Oeri 1996
Dr. Severin Schwan 2013
Peter R. Voser 2011
Professor Dr. Beatrice Weder di Mauro 2006

The following will be nominated for election as new members of the Board of Directors:

Bernard Poussot
Professor Richard P. Lifton, Ph.D.

Christoph Franz, Chairman of Roche said: „I am delighted that we are able to propose two outstanding individuals to be elected as new members of the Board who will bring significant experience from their careers in the pharmaceutical industry and in biomedical research, respectively.”


Change in the enlarged Corporate Executive Committee

Richard Scheller (61), Ph.D., Head of Genentech Research and Early Development (gRED) and member of the enlarged Corporate Executive Committee has decided to retire as of 31 December 2014. As of 1 January 2015 Michael D. Varney (56), Ph.D., currently Head of Small Molecule Drug Discovery, will become Head of gRED and member of the enlarged Corporate Executive Committee of Roche.

Severin Schwan, CEO of Roche, commented about the change: „I thank Richard Scheller for his outstanding contributions to the Roche Group. Genentech developed a number of important medicines under his leadership. Richard also contributed significantly to the successful integration of Genentech into the Roche Group. It is my pleasure that with Mike Varney we could name a successor from within the gRED organization. Mike brings a proven track record in the discovery and development of new medicines as well as considerable experience in leading research organizations.”


About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for Roche (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top